The Neurology Pipeline: A Strategic Review

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• The Neurological Disease Pipeline
  • Agents
  • Companies
    • GlaxoSmithKline
    • Roche
    • Eli Lilly
• Opportunities in the Neurology Pipeline
  • Great Potential for an Effective Neuroprotectant
  • More-Convenient/Safer Formulations of Neurology Drugs
• Market Statistics and Market Outlook
  • Market Statistics
  • Market Drivers and Constraints

Tables

• 1. Descriptions of Neurological Disorders
• 2. Drug Classes Commonly Used to Treat Neurological Disorders
• 3. 2008 Overall R&D Spend of Companies with Leading Neurological Pipelines
• 4. GlaxoSmithKline' s Neurology Pipeline
• 5. Roche' s Neurology Pipeline
• 6. Eli Lilly' s Neurology Pipeline
• 7. Late-Stage Neuroprotectants in the Neurology Pipeline
• 8. 2008 Worldwide Sales of Leading Neurological Drugs
• 9. 2008 Market-Leading Companies, by Neurology Sales
• 10. Patent Expiries of Key Neurology Drugs, 2008-2013
• 11. 2015 Market-Leading Companies, by Estimated Neurology Sales
• 12. 2015 Estimated Worldwide Sales of Leading Neurology Drugs

Figures

• 1. Neurology Pipeline, by Disease
• 2. Neurology Pipeline: NMEs Versus Reformulations
• 3. Neurology Pipeline Agents, by Formulation
• 4. Neurology Pipeline, by Drug Target
• 5. Neurology Pipeline, by Development Phase
• 6. Neurology Pipeline, by Company
• 7. Leading Neurology Pipelines, Number of Agents by Phase
• 8. Leading Neurology Pipelines, Number of Agents by Disease
• 9. Neurology Pipeline, Development Activity by Company Size
• 10. GlaxoSmithKline Neurology Franchise Sales, 2008 and 2015
• 11. Worldwide Neurology Disease Market Growth, 2004-2015
• 12. Neurology Disease Market Growth, by Region, 2004-2015
• 13. Worldwide Sales of Neurology Drug Classes, 2008 and 2015